Author: admin
Ovarian cancer is one of the deadliest gynecological cancers due to most of the cases—approximately 80 percent—being diagnosed in the late stages of the disease.1 The standard of care for ovarian cancer, which is platinum-based chemotherapy and surgery, has not advanced in more than 30 years. But that may be about to change.Researchers at the immunotherapy company IMUNON recently reported results in Gynecologic Oncology from their Phase 1/2 clinical trial testing their DNA-based immunotherapy in women with advanced-stage ovarian cancer.2 They found that their drug, which delivers the gene for the cytokine interleukin-12 (IL-12), directly to the ovarian tumors, led…
Credit: Nephron, CC BY-SA 3.0 , via Wikimedia Commons Researchers at Rutgers University have found that liver cancer can be driven in part by the liver’s failure to dispose of nitrogen waste and that reducing dietary protein may slow tumor growth in people whose livers are already impaired. In a study published in Science Advances, the team found that repressed expression of urea cycle enzymes (UCEs) impairs the functioning of the liver’s ammonia waste-handling machinery which then promotes tumor development by feeding metabolic pathways cancer cells rely on to thrive. “If you have liver disease or damage that prevents your…
The FDA’s Center for Biologics Evaluation and Research (CBER) granted NanoMosaic’s request for an Advanced Manufacturing Technology (AMT) designation for its Nanoneedle technology for multiplex testing of vector genome and capsid titers in AAV gene therapy manufacturing. “The NanoMosaic technology is designed to support upstream and downstream process development, quality control, release testing, and lifecycle management of gene therapy products,” says Qimin Quan, PhD, co-founder and CSO of NanoMosaic. The FDA’s approval for an AMT designation verifies the platform’s ability to enhance efficiency, product quality, and scalability across AAV gene therapy manufacturing, according to Philippe Mourere, CEO, NanoMosaic, who…
Recent reports of Nipah virus (NiV) infections in West Bengal, India, have reignited global concern, prompting public health authorities to prioritize research into this high-mortality pathogen. In response, Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, has announced the accelerated availability and development of critical research tools to support the global scientific community in combating NiV.Nipah virus, a member of the Paramyxoviridae family, is classified by the World Health Organization (WHO) as a priority pathogen due to its epidemic potential and high fatality rate (estimated between 40% to 75%). With no approved vaccines or specific…
Credit: CIPhotos/Getty Images Researchers at Mayo Clinic have developed a base editing therapy for autosomal dominant polycystic kidney disease (ADPKD), a genetic condition affecting one in 1,000 people. Their findings, published recently in Nature Communications, set a new precedent for treating genetic conditions affecting the kidneys, which have historically proven difficult to target with gene editing technologies. “This is the first time we’ve been able to show that base editing can effectively and safely correct a disease-causing mutation in the kidney in a complex biological system,” says Xiaogang Li, PhD, nephrology researcher at Mayo Clinic and senior author of the…
We kick off the very first episode of 2026 with a major legal development. This week, the former CEO of CytoDyn was sentenced to 30 months in prison, more than a year after being convicted on multiple charges including four counts of securities fraud, two counts of wire fraud, and three counts of insider trading. Also, we examine recent investments in artificial intelligence by several major drugmakers, and where they are hoping the technology can make an impact. Then, the latest from 10x Genomics and its plans to expand into clinical diagnostics through new collaboration. And for some research news,…
Beckman Coulter Life Sciences and Automata today announced a strategic partnership that integrates Beckman Coulter Life Sciences liquid handling, genomic and cell analysis technologies with Automata’s AI-ready automation platform to enable faster, more consistent and more scalable experimentation for research organizations. The collaboration brings together Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation and a subsidiary of Danaher Corporation, and Automata, a London-based lab automation company modernizing how R&D laboratories design, execute and scale scientific workflows.The partnership is part of a larger investment in which Danaher Ventures will participate in Automata’s Series C funding round and…
Credit: KATERYNA KON/SCIENCE PHOTO LIBRARY/Getty Images Pancreatic ductal adenocarcinoma is one of the most lethal cancers, largely because it is usually diagnosed too late for effective treatment. Once symptoms appear, the disease has often already spread, leaving surgery, currently the only curative option, off the table for most patients. As a result, only about one in ten people diagnosed with pancreatic cancer survive more than five years. A new NIH-supported study, published in Clinical Cancer Research, suggests that earlier detection may finally be within reach. Researchers at the University of Pennsylvania Perelman School of Medicine and the Mayo Clinic have…
Evidence has been rising over the past few years that the gut microbiome can significantly influence how well cancer treatments work, especially immunotherapies. But the underlying mechanism has remained unclear. Now, a new study reveals how bacteria in the gut can help determine whether the amino acid asparagine (obtained from diet) will increase tumor growth or activate immune cells against the cancer. The findings, published in Cell Microbe and Host in the paper, “Microbiota utilization of intestinal amino acids modulates cancer progression and anticancer immunity,” could lead to a novel cancer treatment approach and monitoring strategy; instead of targeting tumors directly, clinicians…
Credit: Jian Fan / iStock / Getty Images Plus A familiar theme re-emerged at the 2026 J.P. Morgan Healthcare Conference with new urgency: RNA is no longer just a messenger—it’s becoming medicine. Across interviews with leaders from Korro Bio, Trace Neuroscience, and CAMP4 Therapeutics, a picture came into focus of an RNA “middle ground” in genetic medicine, one that sits between permanent DNA editing and conventional small molecules, offering precision with flexibility. Together, these companies are pushing RNA therapeutics beyond silencing genes toward editing, repairing, and even amplifying gene function—often in ways that would be difficult or risky at the…